Subtotal $0.00
Animal health has moved well beyond conventional veterinary treatment. Today, the sector spans vaccines, pharmaceuticals, diagnostics, feed additives, preventive healthcare and technologies designed to improve the health and productivity of both companion and commercial animals. Its importance extends into food security, livestock economics, public health and the increasingly sophisticated care of pets.
The global animal health market attained approximately USD 63.03 billion in 2025 and is projected to expand at a 6.40% CAGR from 2026 to 2035, reaching about USD 117.21 billion by 2035, according to the market estimate used for this analysis. Other research firms report different market totals because of differences in market scope, product categories and inclusion of veterinary services or related technologies.
What remains consistent across these estimates is the underlying direction: animal healthcare is becoming more preventive, technology-enabled and integrated with livestock production and companion-animal wellness.
Key Growth Drivers Shaping the Animal Health Market
The animal health market is being driven by rising pet healthcare spending, increasing demand for animal protein, persistent disease risks, advances in veterinary medicine and greater awareness of preventive healthcare. Diagnostics, vaccines and digital monitoring are becoming increasingly important because earlier intervention can reduce treatment costs and production losses.
For livestock producers, animal health is closely connected with productivity. Healthy cattle, poultry, swine, sheep, goats and fish are more capable of maintaining production efficiency, while disease outbreaks can disrupt farms, supply chains and international trade. The World Organisation for Animal Health (WOAH) estimates that animal diseases destroy more than 20% of global animal production each year, highlighting the economic significance of prevention and disease control.
Disease surveillance is another structural growth driver. WOAH’s 2026 Asia-Pacific reporting illustrates the continuing scale and diversity of disease threats, with hundreds of outbreaks reported across the region during the second quarter of 2026. Rabies, highly pathogenic avian influenza and foot-and-mouth disease were among the reported concerns.
At the same time, companion animals are receiving more sophisticated medical care. Pets are increasingly treated as family members, encouraging owners to spend on preventive medicines, diagnostics, dental care, dermatology, chronic disease management and advanced procedures. Zoetis, for example, reported that companion-animal products represented approximately 70% of its 2025 revenue, illustrating the commercial importance of this segment for a major global animal-health company.
The Growing Shift Toward Preventive Care
Prevention is becoming central because vaccination, parasite control, surveillance and early diagnosis can reduce the biological and financial consequences of disease. This is particularly relevant where animal health affects food production or diseases have zoonotic potential.
WOAH reported in 2025 that 47% of animal diseases reported in its analysis had zoonotic potential, while also highlighting uneven access to livestock vaccines. The issue is therefore not simply about treating sick animals; it is increasingly about preventing disease from spreading through farms, communities and supply chains.
Market Segmentation by Animal Type and Product
The market is broadly divided between commercial animals and companion animals, while major product categories include vaccines, pharmaceuticals, feed additives, diagnostics and other animal-health solutions. Each category addresses a different point in the animal-care value chain, from prevention and treatment to monitoring and productivity management.
Commercial animals generate demand across cattle, poultry, swine, sheep, goats and aquatic species. Producers generally evaluate animal-health products in terms of disease prevention, mortality reduction, feed efficiency, reproductive performance, production quality and compliance with food-safety requirements. Vaccines, pharmaceuticals and feed additives therefore have an important role in production-animal management.
Companion animals, particularly dogs and cats, create a different demand profile. Owners and veterinarians increasingly seek treatments for chronic conditions, parasites, dermatological problems, pain, infectious diseases and age-related disorders. Diagnostic testing is also becoming more important because veterinarians can make treatment decisions using increasingly detailed laboratory and point-of-care information.
Pharmaceuticals remain a major part of the market. Grand View Research estimates that pharmaceuticals accounted for about 43.1% of global animal-health revenue in 2025 under its market definition. The category includes products such as anti-infectives, parasiticides, anti-inflammatory medicines, analgesics and other veterinary treatments.
Vaccines occupy a particularly strategic position because they can prevent disease rather than simply respond to it. They are also increasingly connected to antimicrobial-resistance strategies. In 2026, WOAH Members adopted an updated Global Action Plan on Antimicrobial Resistance for 2026–2036, reinforcing the role of coordinated action across animal, human and environmental health.
Diagnostics represent another increasingly valuable component. Molecular testing, laboratory diagnostics, point-of-care systems and digital monitoring can help veterinarians identify disease earlier and select appropriate interventions.
Applications Across Veterinary Care and Livestock Production
Animal health products are used throughout veterinary hospitals and clinics, diagnostic centres, animal-care and rehabilitation facilities, livestock operations and other healthcare settings. Their practical value ranges from routine vaccination and parasite prevention to complex diagnostics and disease-control programmes.
Veterinary hospitals and clinics remain critical points of care, particularly in companion-animal medicine. These facilities use pharmaceuticals, vaccines, diagnostic equipment and laboratory services to manage both acute and chronic conditions. The increasing sophistication of veterinary procedures has also expanded demand for specialised diagnostics and therapeutic products.
Diagnostic centres play a different but complementary role. Testing can identify infectious diseases, monitor organ function, support preventive screening and provide laboratory evidence for treatment decisions. The shift toward earlier diagnosis is important commercially because diagnostics can create recurring demand rather than relying exclusively on treatment after symptoms become severe.
In livestock production, animal health is closely tied to farm economics. Vaccination programmes, parasite control, biosecurity, feed additives and disease monitoring can influence mortality, growth rates, reproduction and the consistency of animal-derived products.
The connection also extends to international trade. Disease outbreaks can result in movement restrictions, market-access problems and significant losses for producers. Consequently, governments, veterinary authorities and private companies have incentives to strengthen surveillance and preventive health infrastructure.
Regional Market Trends and Growth Opportunities
North America remains a major animal-health market because of established veterinary infrastructure, high companion-animal expenditure, sophisticated livestock production and strong demand for advanced diagnostics and pharmaceuticals. Asia Pacific, however, represents an important growth opportunity because of its large animal population, expanding veterinary infrastructure and rising demand for animal protein and pet healthcare.
The regional landscape is not uniform. In North America, the market benefits from relatively mature veterinary networks and high-value companion-animal healthcare. The United States is identified by Grand View Research as the largest country market in its 2025 assessment.
Europe combines developed veterinary systems with strong regulatory attention to animal welfare, food safety and antimicrobial use. Disease events affecting livestock, including outbreaks involving bluetongue and other infectious diseases, continue to reinforce the importance of surveillance and prevention.
Asia Pacific has particularly strong long-term potential. Large livestock populations, expanding urban pet ownership, rising disposable incomes and improving veterinary infrastructure are broadening the addressable market. At the same time, disease surveillance remains a practical challenge. WOAH’s 2026 reports show continuing disease activity across the region, demonstrating why diagnostic capacity, vaccination and early-warning systems remain commercially and strategically important.
India illustrates this development. Grand View Research estimates that India’s animal health market was worth USD 1.97 billion in 2024 and forecasts a 13.9% CAGR from 2025 to 2030. Government programmes, increasing veterinary investment, diagnostics adoption and a growing startup ecosystem are among the factors identified as supporting expansion.
Latin America and the Middle East and Africa also present opportunities linked to livestock production, disease control, food security and improvements in veterinary access. However, infrastructure, affordability, regulatory differences and uneven diagnostic capacity can influence the pace of market development.
Technology and Innovation Transforming Animal Healthcare
Technology is shifting animal healthcare from predominantly reactive treatment toward earlier detection, continuous monitoring and data-supported decision-making. Artificial intelligence, advanced diagnostics, digital veterinary platforms, connected devices and improved laboratory technologies are expanding what veterinarians and producers can measure and manage.
For companion animals, technology can support remote monitoring, appointment management, diagnostic interpretation and ongoing chronic-care programmes. Wearable devices can potentially provide information about activity, behaviour and other indicators that may help owners and veterinarians identify changes requiring attention.
In livestock operations, connected sensors and monitoring systems can help identify changes in movement, feeding behaviour, temperature or production performance. The commercial value comes from converting those signals into earlier interventions, potentially reducing losses and improving resource efficiency.
Diagnostics are also becoming more sophisticated. Molecular testing and other advanced laboratory methods can provide greater specificity and speed than traditional approaches in appropriate settings. This matters during outbreaks, where rapid identification can influence isolation, treatment and vaccination decisions.
However, technology does not remove the need for veterinary expertise. Data quality, interpretation, regulatory requirements, connectivity and the economics of adoption remain important considerations. The strongest opportunities are therefore likely to come from technologies that solve a defined clinical or production problem rather than from digitisation for its own sake.
Competitive Landscape and Leading Industry Participants
The competitive landscape includes large multinational animal-health companies with broad pharmaceutical and vaccine portfolios, specialist diagnostics businesses and regional manufacturers. Competition increasingly centres on research and development, product efficacy, regulatory capability, distribution networks, clinical relationships and the ability to combine products with diagnostic or digital solutions.
Major companies identified in the market include Elanco Animal Health Incorporated, Merck Animal Health, Zoetis Inc., Biogenesis Bago, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Heska Corporation, IDEXX Laboratories, Inc., Virbac S.A. and Vetoquinol SA, alongside other regional and specialist participants.
Zoetis provides a useful illustration of how the competitive model is evolving. The company reported approximately 300 product lines spanning companion animals and livestock in its 2025 annual report, with major categories including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, pharmaceuticals and diagnostics.
IDEXX represents another important dimension of competition through veterinary diagnostics and laboratory services, while companies such as Virbac and Vetoquinol have established positions across veterinary pharmaceuticals and animal-health products.
Competition is also becoming more regional. In emerging markets, companies need to balance advanced products with affordability, distribution and local disease patterns. India, for example, has a combination of multinational companies and domestic manufacturers serving livestock and companion-animal needs, creating a competitive environment where local production and distribution can be as important as global research capabilities.
Challenges Influencing Future Market Development
The industry’s growth prospects are substantial, but affordability, antimicrobial resistance, regulatory complexity, disease-reporting gaps and uneven veterinary infrastructure remain important constraints. These challenges can affect both the adoption of products and the industry’s ability to respond quickly to emerging disease threats.
One major issue is antimicrobial resistance. Veterinary healthcare increasingly needs to balance effective treatment with responsible antimicrobial use. Vaccines, diagnostics and preventive management can help reduce unnecessary antimicrobial exposure, but adoption depends on availability, cost, producer practices and veterinary capacity.
Regulatory requirements also vary across markets. Obtaining approvals for pharmaceuticals, vaccines and diagnostics can require significant clinical evidence, manufacturing controls and post-market monitoring. This raises development costs and can make market entry more difficult for smaller companies.
Access remains another challenge. Advanced veterinary products may be readily available in wealthier markets while farmers and animal owners in lower-income regions can face shortages of medicines, vaccines, trained professionals and diagnostic services. WOAH has highlighted both investment gaps and differences in veterinary capacity as important issues for global animal-health resilience.
Disease reporting is particularly important. In Asia Pacific, WOAH research found that limited capability and organisational knowledge can be significant barriers to timely disease notification, showing that stronger surveillance requires not only technology but also trained personnel and effective systems.
Animal Health Market Outlook Through 2035
The animal health market is expected to remain a growth industry as prevention, diagnostics, companion-animal care and livestock disease management become increasingly important. Based on the market estimate used for this analysis, the sector is projected to increase from approximately USD 63.03 billion in 2025 to USD 117.21 billion by 2035 at a 6.40% CAGR.
The most important opportunity is not simply the rising volume of veterinary products. It is the gradual integration of prevention, treatment, diagnostics, data and professional services into a more connected animal-health ecosystem.
Commercial livestock producers will continue to seek solutions that protect productivity while meeting food-safety and sustainability requirements. Companion-animal owners will continue to demand more sophisticated and personalised care. Meanwhile, governments and international organisations will have strong incentives to strengthen disease surveillance because animal-health failures can affect food systems, trade and public health.
The market should therefore be viewed as a combination of several interconnected businesses rather than a single pharmaceutical category. Companies able to address real clinical and production needs through effective medicines, vaccines, diagnostics and supporting technologies will operate in a sector where demand is increasingly linked to prevention and long-term animal wellbeing.
Conclusion: A More Preventive and Technology-Driven Animal Health Industry
The animal health market sits at the intersection of veterinary medicine, agriculture, food security, biotechnology and companion-animal care. Its growth is being shaped by a fundamental shift toward prevention, earlier diagnosis and more sophisticated treatment.
From vaccines that protect livestock populations to advanced diagnostics used in veterinary clinics, the industry’s products increasingly influence both animal wellbeing and economic resilience. Continued disease threats, antimicrobial-resistance concerns, rising pet-care expenditure and technological innovation are likely to keep animal health strategically important through 2035.
The strongest long-term opportunities will come from solutions that deliver measurable value: preventing disease, detecting problems earlier, improving treatment outcomes, supporting productive livestock systems and making quality veterinary care more accessible. In that sense, animal health is not simply a growing healthcare market; it is an increasingly important component of resilient food systems and responsible animal care.